Stroke Risk and Antithrombotic Treatment During Follow-up of Patients With Ischemic Stroke and Cortical Superficial Siderosis.
Joan Martí-FàbregasPol Camps-RenomJonathan G BestAnna Ramos-PachonMarina Guasch-JiménezAlejandro Martinez-DomeñoDaniel Guisado-AlonsoBeatriz M Gómez-AnsónGareth AmblerDuncan WilsonKeon-Joo LeeJae-Sung LimHee Joon BaeMasayuki ShiozawaMasatoshi KogaKazunori ToyodaMichael G HennericiHugues ChabriatEric JouventDebbie Yuen Kwun WongHenry MakGary Kui Kai LauYoung Dae KimTae Jin SongJi-Hoe HeoSebastian EppingerThomas GattringerEnder UysalDerya Selçuk DemirelliNatan BornsteinEinor Ben AssayagHen HalleviJeremy A MoladMasashi NishiharaJun TanakaHideo HaraYusuke YakushijiShelagh B CouttsEric Edward SmithAlexandros A PolymerisBenjamin WagnerDavid Julian SeiffgePhilippe A LyrerNils PetersStefan T EngelterRustam Al-Shahi SalmanHans Rudolf JägerGregory Yoke Hong LipMartina Béatrice GoeldlinLeonidas PanosChristopher Charles KarayiannisThanh G PhanVelandai K SrikanthNicolas ChristSarah GunkelFelix FluriThomas Wai Hong LeungYannie O Y SooWinnie ChuJill AbrigoCarmen BarbatoSimone BrowningRobert J SimisterAnne-Marie MendykRégis BordetSaima HilalBibek GyanwaliChristopher ChenSimon JungDilek Necioglu OrkenDavid WerringLuís Prats-Sáncheznull nullPublished in: Neurology (2022)
Patients with IS or TIA with cSS are at increased risk of stroke (ICrH or IS) during follow-up; the risk of IS exceeds that of ICrH for patients receiving antiplatelet or anticoagulant treatment alone, but the risk of ICrH exceeds that of IS in patients receiving both treatments. The findings suggest that either antiplatelet or anticoagulant treatment alone should not be avoided in patients with cSS, but combined antithrombotic therapy might be hazardous. Our findings need to be confirmed by randomized clinical trials.